###begin article-title 0
Acute-Phase Serum Amyloid A: An Inflammatory Adipokine and Potential Link between Obesity and Its Metabolic Complications
###end article-title 0
###begin p 1
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: The authors have declared that no competing interests exist. 
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Obesity is associated with low-grade chronic inflammation, and serum markers of inflammation are independent risk factors for cardiovascular disease (CVD). However, the molecular and cellular mechanisms that link obesity to chronic inflammation and CVD are poorly understood.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 625 626 625 626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 635 636 635 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 649 650 649 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 659 660 659 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 771 772 771 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 832 833 832 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 979 980 979 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 990 991 990 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 149 161 <span type="species:ncbi:9606">participants</span>
###xml 193 200 <span type="species:ncbi:9606">persons</span>
###xml 313 318 <span type="species:ncbi:9606">human</span>
###xml 393 399 <span type="species:ncbi:10090">murine</span>
###xml 486 491 <span type="species:ncbi:9606">human</span>
###xml 756 768 <span type="species:ncbi:9606">participants</span>
Acute-phase serum amyloid A (A-SAA) mRNA levels, and A-SAA adipose secretion and serum levels were measured in obese and nonobese individuals, obese participants who underwent weight-loss, and persons treated with the insulin sensitizer rosiglitazone. Inflammation-eliciting activity of A-SAA was investigated in human adipose stromal vascular cells, coronary vascular endothelial cells and a murine monocyte cell line. We demonstrate that A-SAA was highly and selectively expressed in human adipocytes. Moreover, A-SAA mRNA levels and A-SAA secretion from adipose tissue were significantly correlated with body mass index ( r = 0.47; p = 0.028 and r = 0.80; p = 0.0002, respectively). Serum A-SAA levels decreased significantly after weight loss in obese participants ( p = 0.006), as well as in those treated with rosiglitazone ( p = 0.033). The magnitude of the improvement in insulin sensitivity after weight loss was significantly correlated with decreases in serum A-SAA ( r = -0.74; p = 0.034). SAA treatment of vascular endothelial cells and monocytes markedly increased the production of inflammatory cytokines, e.g., interleukin (IL)-6, IL-8, tumor necrosis factor alpha, and monocyte chemoattractant protein-1. In addition, SAA increased basal lipolysis in adipose tissue culture by 47%. 
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 54 60 <span type="species:ncbi:9606">humans</span>
A-SAA is a proinflammatory and lipolytic adipokine in humans. The increased expression of A-SAA by adipocytes in obesity suggests that it may play a critical role in local and systemic inflammation and free fatty acid production and could be a direct link between obesity and its comorbidities, such as insulin resistance and atherosclerosis. Accordingly, improvements in systemic inflammation and insulin resistance with weight loss and rosiglitazone therapy may in part be mediated by decreases in adipocyte A-SAA production.
###end p 7
###begin title 8
Editors' Summary
###end title 8
###begin title 9
Background.
###end title 9
###begin p 10
###xml 495 501 <span type="species:ncbi:9606">people</span>
###xml 683 689 <span type="species:ncbi:9606">people</span>
Obesity often alters an individual's overall metabolism, which in turn leads to complications like diabetes, high blood pressure, and an increased risk of cardiovascular disease (disease of the heart and blood vessels, such as stroke or heart attacks). Having established a strong link between inflammation and cardiovascular disease, scientists now think that obesity might cause persistent low-level inflammation, and that this is the reason for the cardiovascular problems seen in many obese people. By better understanding the links between obesity, inflammation, and cardiovascular disease, the hope is that scientists may be able to find medications that can be given to obese people to reduce their risk of heart attacks and strokes.
###end p 10
###begin title 11
Why Was This Study Done?
###end title 11
###begin p 12
###xml 447 453 <span type="species:ncbi:9606">people</span>
Previous research had suggested that a substance in the blood called A-SAA, which is raised by inflammation, might be a "missing link" between inflammation and cardiovascular disease, since an individual's baseline level of A-SAA is associated with the risk for cardiovascular disease (in other words, the higher the A-SAA, the higher the risk of cardiovascular disease). In the new study, researchers wanted to know whether the reason that obese people have a higher risk of cardiovascular disease is because they have higher blood levels of A-SAA.
###end p 12
###begin title 13
What Did the Researchers Do and Find?
###end title 13
###begin p 14
###xml 22 28 <span type="species:ncbi:9606">people</span>
###xml 170 176 <span type="species:ncbi:9606">people</span>
###xml 473 479 <span type="species:ncbi:9606">people</span>
They found that obese people had higher levels of A-SAA in their blood. A-SAA appears to be produced in fat cells (or adipocytes) and then released into the blood. Obese people have higher numbers of fat cells, which could by itself account for the higher blood levels of A-SAA, but the researchers also found that the average fat cell from an obese individual produces and secretes higher levels of A-SAA than fat cells from lean individuals. When the researchers studied people who underwent weight loss, they found that A-SAA levels fell in response to weight loss, and this was associated with improvements in their metabolism. They then studied obese individuals who received the diabetes drug rosiglitazone (which is known to reduce inflammation). They found that even though these individuals did not lose weight, their A-SAA levels dropped as their metabolism improved. Trying to get at the mechanisms by which A-SAA might cause inflammation and diabetes, the researchers found that exposure to A-SAA can stimulate the activation of proinflammation molecules in a number of different cells, including blood vessel cells. It can also stimulate cells to break down fat stores and release fats, which could lead to metabolic complications and ultimately contribute to diabetes.
###end p 14
###begin title 15
What Do These Findings Mean?
###end title 15
###begin p 16
###xml 406 414 <span type="species:ncbi:9606">patients</span>
Together with similar results from other studies, the findings here suggest that A-SAA could promote inflammation, and that elevated levels of A-SAA in obese individuals could contribute to the chronic low-level inflammatory state that puts them at higher risk for cardiovascular complications. The authors speculate that drugs that reduce the blood levels of A-SAA might be useful as treatments for obese patients (to lower their risk of heart attacks and strokes). However, as they acknowledge, additional studies are needed to establish that A-SAA is indeed a causal link between obesity and inflammation and whether it plays a major role before it could be considered a promising drug target.
###end p 16
###begin title 17
Additional Information.
###end title 17
###begin p 18
Please access these Web sites via the online version of this summary at . 
###end p 18
###begin p 19
* MedlinePlus pages on  and 
###end p 19
###begin p 20
* US Centers for Disease Control and Prevention pages on  and 
###end p 20
###begin p 21
* Wikipedia pages on  and  (note: Wikipedia is a free Internet encyclopedia that anyone can edit) 
###end p 21
###begin p 22
Higher levels of Acute-phase serum amyloid A (A-SAA), a proinflammatory adipokine, in obese individuals may contribute to the chronic low-level inflammatory state that puts them at higher risk for cardiovascular complications.
###end p 22
###begin title 23
Introduction
###end title 23
###begin p 24
###xml 346 347 346 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b001">1</xref>
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b002">2</xref>
###xml 421 422 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b003">3</xref>
###xml 424 425 424 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b004">4</xref>
Complications of excess fat mass, particularly central or visceral adipose tissue, include insulin resistance and resulting hyperinsulinemia, glucose intolerance and diabetes, hypertension, hyperlipidemia, and a prothrombotic state. This constellation of obesity-related complications, often referred to as the metabolic syndrome or syndrome X [ 1, 2], markedly increases risk of cardiovascular disease (CVD) and death [ 3, 4]. 
###end p 24
###begin p 25
###xml 570 571 570 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b005">5</xref>
###xml 707 708 707 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b003">3</xref>
###xml 710 711 710 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b006">6</xref>
###xml 822 823 822 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b007">7</xref>
###xml 825 826 825 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b008">8</xref>
Although the link between excess body fat and the metabolic and cardiovascular sequelae is well documented clinically and epidemiologically, the molecular and cellular underpinnings for this link are poorly understood. Excess and/or dysfunctional adipose tissue is associated with chronic low-grade systemic inflammation, which is also associated with CVD. For example, a modest elevation in C-reactive protein (CRP), an acute-phase reactant protein produced by the liver and a long-known marker of inflammation, has been shown to be predictive of CVD risk and events [ 5]. Indeed, measurement of CRP is now recommended in some clinical settings to stratify individual CVD risk and to help direct therapy [ 3, 6]. Serum amyloid A (SAA), another acute-phase reactant protein, has also been shown to be a predictor of CVD [ 7, 8]. Whether these acute-phase reactant proteins are directly involved in inflammation and the atherosclerotic process or simply markers of these processes is not known. 
###end p 25
###begin p 26
###xml 326 327 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b009">9</xref>
###xml 455 457 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b010">10</xref>
###xml 459 461 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b011">11</xref>
###xml 660 662 656 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b012">12</xref>
###xml 958 960 954 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b013">13</xref>
###xml 962 964 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b014">14</xref>
###xml 875 880 <span type="species:ncbi:9606">human</span>
###xml 1202 1208 <span type="species:ncbi:9606">humans</span>
Adipose tissue is "inflamed" in obesity, with decreased expression of the anti-inflammatory adipokine adiponectin and increased secretion of a variety of proinflammatory cytokines, e.g., tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-6, and prothrombotic factors such as plasminogen activator inhibitor-1 (PAI-1) [ 9]. Infiltration of adipose tissue by macrophages is in part responsible for this inflammatory process associated with obesity [ 10, 11]. However, the upstream regulator(s) responsible for the inflammatory state in adipose tissue and the role adipose tissue-derived inflammatory factors play in systemic inflammation remain unclear [ 12]. In a systematic search of differentially expressed genes between adipocytes and stromal vascular cells, we noted that serum amyloid A1 and A2 (SAA1 and SAA2, collectively called A-SAA) were highly expressed in human adipocytes, which was unexpected but in agreement with recent publications [ 13, 14]. A-SAA has been regarded as merely an inflammation marker and thought to be produced primarily in liver. In this study, we aimed to test the hypothesis that adipose A-SAA may be a molecular link between obesity and its comorbidities in humans. 
###end p 26
###begin title 27
Methods
###end title 27
###begin title 28
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 6 18 <span type="species:ncbi:9606">Participants</span>
Human Participants
###end title 28
###begin p 29
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b019">19</xref>
###xml 76 81 <span type="species:ncbi:9606">human</span>
###xml 164 176 <span type="species:ncbi:9606">participants</span>
###xml 518 530 <span type="species:ncbi:9606">participants</span>
###xml 662 674 <span type="species:ncbi:9606">participants</span>
The Institutional Review Boards of the respective institutions approved all human studies, and each volunteer provided written informed consent to participate. All participants were healthy according to medical history, physical examination, and laboratory testing unless otherwise specified in the protocols. The individuals studied showed no clinical or laboratory evidence of acute inflammation such as fever or elevated white blood cell counts. Abdominal adipose tissue samples were obtained from overnight-fasted participants by aspiration with a 4-mm cannula under local anesthesia with lidocaine as previously described [ 19] or obtained from nondiabetic participants undergoing intra-abdominal surgeries. All blood samples were stored at -80 degreesC until used. 
###end p 29
###begin title 30
Cross-sectional study of body mass index and serum A-SAA levels.
###end title 30
###begin p 31
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b020">20</xref>
###xml 285 287 285 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 420 422 420 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
Participants were part of the previously described Amish Family Diabetes Study [ 20]. Initially, A-SAA levels were measured in plasma samples from 19 sex- and age-matched (age within 5 y) sets of nondiabetic sibling pairs with a discordance in body mass index (BMI) of at least 3 kg m -2. These 38 individuals were then included in an expanded set of 134 nondiabetic individuals with BMIs ranging from 17.0 to 41.8 kg m -2. Blood samples for A-SAA measurements were obtained from an antecubital vein after an overnight fast. 
###end p 31
###begin title 32
Effect of weight loss on A-SAA and insulin sensitivity.
###end title 32
###begin p 33
###xml 67 69 65 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 459 461 451 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 488 490 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b021">21</xref>
###xml 1575 1577 1567 1569 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 1582 1584 1574 1576 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 149 154 <span type="species:ncbi:9606">women</span>
###xml 752 764 <span type="species:ncbi:9606">participants</span>
###xml 846 858 <span type="species:ncbi:9606">participants</span>
###xml 983 995 <span type="species:ncbi:9606">participants</span>
###xml 1154 1159 <span type="species:ncbi:9606">Women</span>
Thirty-three sedentary, overweight or obese (BMI 32.3 +/- 4.0 kg m -2, mean +/- standard deviation [SD]), postmenopausal (58 +/- 5.7 y, mean +/- SD) women were studied before and after a 6-mo weight loss program. The intervention consisted of weekly outpatient classes with a dietitian on the principles of a hypocaloric dietary program that followed the American Heart Association (AHA) Step I guidelines with restriction of caloric intake by 250-350 kcal d -1 as previously described [ 21]. Fat mass was determined by dual-energy X-ray absorptiometry (Model DPX-L; Lunar Radiation, Madison, Wisconsin, United States) using the 1.3z DPX-L extended analysis program. Fasting serum levels of A-SAA were measured before and after the intervention in all participants. Subcutaneous abdominal fat biopsies were obtained at baseline in a subset of 31 participants under local anesthesia for the ex vivo studies of adipose A-SAA expression and/or secretion (described below). Eight of the participants underwent 3-h hyperinsulinemic-euglycemic clamp studies at baseline and after completion of the weight loss program to assess changes in insulin sensitivity. Women were weight-stabilized (< 1 kg) for at least 2 wk prior to metabolic testing before and after weight loss. All testing was performed in the morning after a 12-h overnight fast. Arterialized blood was obtained from a dorsal heated hand vein. Basal plasma glucose and insulin levels were measured in the fasted state. A 10 min priming with insulin followed by a continuous intravenous infusion of insulin (240 pmol m -2 min -1, Humulin, Eli Lilly, Indianapolis, Indiana, United States) was performed for 180 min. Glucose was infused at a variable rate to keep the plasma glucose, measured every 5 min, at the basal (fasting) level. Blood was also drawn every 10 min for the determination of plasma insulin levels. Plasma glucose was measured with the glucose oxidase method (Beckman Instruments, Fullerton, California, United States). Insulin was determined by radioimmunoassay (Linco, St. Louis, Missouri, United States). 
###end p 33
###begin p 34
###xml 390 392 388 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 415 417 411 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 206 217 <span type="species:ncbi:9606">participant</span>
The mean concentration of glucose and insulin was calculated for each sample time point. The trapezoidal rule was used to calculate the integrated response over 30-min intervals from 30 to 180 min for each participant. The integrated response was divided by its time interval to compute mean concentrations. Plasma glucose and insulin levels during the clamps averaged 5.17 +/- 0.10 mmol l -1 and 474 +/- 14 pmol l -1, respectively. This was 97.7% +/- 0.2% of the desired goal with a coefficient of variation of 5.2% +/- 0.4% in all clamps. Glucose utilization (M) for the 120- to 180-min interval was calculated from the amount of glucose infused after correction for glucose equivalent space (glucose space correction). 
###end p 34
###begin title 35
Effect of treatment with the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone on A-SAA.
###end title 35
###begin p 36
###xml 104 106 100 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 174 176 168 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 206 208 200 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 48 60 <span type="species:ncbi:9606">participants</span>
Eight healthy, nondiabetic, overweight or obese participants (age 44.7 +/- 9.1 y, BMI 30.8 +/- 3.1 kg m -2, mean +/- SD) were recruited and treated with rosiglitazone 4 mg d -1 for 4 wk, followed by 8 mg d -1 for 8 wk. Fasting serum levels of A-SAA were measured before and at 12 wk into the rosiglitazone intervention. At the same time points, subcutaneous abdominal fat biopsies were obtained under local anesthesia for ex vivo studies of adipose A-SAA expression and secretion (described below). 
###end p 36
###begin title 37
Adipose Tissue Fractionation and Microarray Analysis
###end title 37
###begin p 38
###xml 495 496 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 624 625 624 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 25 30 <span type="species:ncbi:9606">human</span>
###xml 96 101 <span type="species:ncbi:9606">women</span>
###xml 949 954 <span type="species:ncbi:9606">human</span>
For microarray analysis, human omental and subcutaneous adipose tissues were obtained from four women (two obese, two nonobese) undergoing semielective intra-abdominal surgery at the University of Maryland Medical Center. Isolated adipocytes and stromal-vascular cells (SVCs) were obtained by collagenase digestion (final concentration 2 mg of collagenase per gram of fat tissue) in Kreb Ringer bicarbonate buffer containing 4% albumin and 200 nM adenosine (KRB-A). After centrifugation at  200 g for 1-2 min, the medium below the floating adipocytes (containing the SVCs) was removed and subjected to centrifugation at 800 g for 5 min. The pelleted SVCs were resuspended in KRB-A and washed three times using the same procedure. The floating adipocytes were washed three additional times with KRB-A. RNA was extracted from adipocyte and SVC fractions, and microarray analysis was conducted using Affymetrix (Santa Clara, California, United States) human U133A chips according to the manufacturer's instructions. 
###end p 38
###begin title 39
Northern Analysis
###end title 39
###begin p 40
###xml 1091 1093 1090 1092 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 417 422 <span type="species:ncbi:10090">mouse</span>
###xml 434 439 <span type="species:ncbi:9606">human</span>
###xml 549 554 <span type="species:ncbi:9606">Human</span>
###xml 617 623 <span type="species:ncbi:10090">murine</span>
###xml 723 728 <span type="species:ncbi:9606">human</span>
###xml 739 744 <span type="species:ncbi:10090">mouse</span>
###xml 853 858 <span type="species:ncbi:10090">mouse</span>
Human adipose tissue and liver specimens were purchased from the National Disease Research Interchange (Philadelphia, Pennsylvania, United States), and total RNAs were prepared with Trizol (Invitrogen, Carlsbad, California, United States) according to the manufacturer's instructions. All other RNAs were purchased from Clontech (Palo Alto, California, United States). Total RNA (15 mug) extracted from the specified mouse (C57BL) or human tissue was subjected to agarose gel electrophoresis and blotted onto Nylon membranes using standard methods. Human SAA2 cDNA corresponding to nucleotides 1-536 of BC020795, and murine SAA2 cDNA corresponding to nucleotides 1-565 of U60438, were used as probes. These probes are 97% (human) and 95% (mouse) identical to SAA1 sequence and thus would be expected to hybridize to both SAA1 and SAA2. By contrast, the mouse SAA2 probe was only 62% identical to SAA3 mRNA and thus would not be expected to hybridize to SAA3 mRNA under the stringent wash conditions used. The probes were random-labeled (Stratagene, La Jolla, California, United States) with 32P-dCTP, and hybridization was carried out at 65 degreesC in Rapid-Hyb buffer (Amersham Biosciences, Piscataway, New Jersey, United States). Blots were washed twice with 0.5x SSC/1% SDS at 65 degreesC (stringent wash), and visualized by PhosphoImager (Amersham Biosciences). 
###end p 40
###begin title 41
RT-PCR Analysis
###end title 41
###begin p 42
###xml 401 406 <span type="species:ncbi:9606">human</span>
###xml 592 597 <span type="species:ncbi:9606">human</span>
###xml 855 860 <span type="species:ncbi:9606">Human</span>
For semiquantitative RT-PCR analysis, reverse transcription was carried out in a reaction containing 1 mug of total RNA, poly-dT primer, and MMLV reverse transcriptase using the Advantage kit (Clontech, Palo Alto, California, United States). PCR was performed under conditions typically consisting of 28 cycles of 94 degreesC for 30 s, 55 degreesC for 30 s, and 72 degreesC for 60 s. For detection of human A-SAA mRNA in fractionated adipocytes and SVCs, primers 5'- GAGAGAAGCCAATTACATCGGC -3' and 5'- AGTATTTCTCAGGCAGGCCAGC -3', which fully match both SAA1 and SAA2, were used. In addition, human SAA1 and SAA2 mRNAs were quantitated individually by RT-PCR using a common forward primer 5'- ATGGGGCTCGGGACATGTGGAG -3', which was paired with reverse primer 5'- AGTCCTCCGCACCATGGCCTGT -3' (SAA1-specific) or 5'- AGTCCTCCGCACCATGGCCAAA -3' (SAA2-specific). Human beta-actin was amplified as a control with primers 5'- TTAATGTCACGCACGATTTCC -3' and 5'- AGACCTTCAACACCCCAGCCA -3'. RT-PCR products were electrophoresed on a 1% agarose gel, stained with ethidium bromide, and visualized by UV transillumination. 
###end p 42
###begin p 43
###xml 473 474 473 474 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 565 590 565 590 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CT SAA &#8722; CT cyclophilin A</sup>
The level of adipose A-SAA mRNA expression was more accurately quantitated by real-time PCR. Applied Biosystems (ABI, Foster City, California, United States) TaqMan PCR kits with commercially available assay-by-design primers were used on an ABI PRISM 7900 Sequence Detection System. The primers and probe for SAA match both SAA1 and SAA2 genes and therefore measure total A-SAA (SAA1 and SAA2) mRNA. Cyclophilin A mRNA was used as an internal standard. Threshold cycle (C T) values were obtained and relative gene expression was calculated using the formula (1/2) CT SAA - CT cyclophilin A. 
###end p 43
###begin title 44
SAA Secretion from Adipose Tissue
###end title 44
###begin p 45
###xml 246 248 244 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 263 264 259 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 323 324 319 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 402 403 398 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 636 638 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b022">22</xref>
###xml 194 199 <span type="species:ncbi:9606">women</span>
###xml 290 295 <span type="species:ncbi:9606">women</span>
###xml 339 351 <span type="species:ncbi:9606">participants</span>
To examine the relationship between adipose A-SAA secretion and BMI, and regulation by weight loss and rosiglitazone treatment, adipose tissue fragments were obtained at biopsy in premenopausal women over a range of BMI values (26.8 +/- 4.2 kg m -2, mean +/- SD, n = 16), in postmenopausal women subjected to weight loss ( n = 33), and in participants before and after 12 wk of rosiglitazone therapy ( n = 7). Adipose tissue fragments were incubated for 3 h in M199 medium containing 1% BSA, and the medium was collected and stored at -80 degreesC until analysis for A-SAA. Adipocyte size was determined by a photomicrographic method [ 22]. 
###end p 45
###begin p 46
###xml 118 120 118 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b023">23</xref>
###xml 148 153 <span type="species:ncbi:9606">human</span>
For ex vivo studies of the regulation of SAA secretion, adipose organ culture was performed as previously described [ 23]. In a sterile hood, fresh human subcutaneous adipose tissue was minced into 5- to 10-mg pieces, washed with warm sterile saline, and cultured with no hormones, 25 nM dexamethasone (American Pharmaceutical Partners, Schaumburg, Illinois, United States), 7 nM insulin (Novo Nordisk, Princeton, New Jersey, United States), or a combination of these hormones, with and without rosiglitazone (1 muM ) (GlaxoSmithKline, Philadelphia, Pennsylvania, United States). The culture medium was changed daily and A-SAA was assayed in the conditioned medium on day 2. 
###end p 46
###begin title 47
Effect of SAA on Cytokine Production
###end title 47
###begin p 48
###xml 414 416 414 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 1229 1231 1228 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1329 1330 1328 1329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 1509 1511 1507 1509 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 8 13 <span type="species:ncbi:9606">human</span>
###xml 275 280 <span type="species:ncbi:9606">Human</span>
###xml 387 398 <span type="species:ncbi:9606">participant</span>
###xml 703 709 <span type="species:ncbi:9913">bovine</span>
###xml 914 919 <span type="species:ncbi:9606">human</span>
###xml 1068 1073 <span type="species:ncbi:9606">human</span>
Primary human coronary artery endothelial cells were purchased from Cambrex (Walkersville, Maryland, United States) and grown in endothelial cell basal medium-2 (EBM-2) supplemented with EGM-2 BulletKit. All experiments were conducted between the third to fifth subcultures. Human primary adipose SVCs from the subcutaneous depot were isolated as described as above from a normal female participant (BMI 27.5 kg m -2) who underwent elective abdominal reconstructive surgery. The SVCs were cultured in complete EGM-2, and subcultures between the second to third subcultures were used. RAW264 monocytes ( ATCC , Manassas, Virginia, United States) were grown in RPMI1640 medium supplemented with 10% fetal bovine serum. These cells were seeded on six-well tissue culture plates at about 75% confluence and grown to 90%-95% confluence. The growth medium was replaced with supplement-free media (EBM-2 basal medium for human coronary artery endothelial cells and RPMI1640 for RAW264 monocytes). The cells were treated 1 h after the medium change with recombinant synthetic human apo-SAA (Peprotech, Rocky Hill, New Jersey, United States), or vehicle (PBS). The endotoxin level for this commercial preparation was less than 0.1 ng mug -1 protein. The conditioned medium was collected 8 h after SAA treatment by centrifugation at 2,000 g for 5 min and frozen until use for cytokine analysis. To examine the effect of SAA on adiponectin secretion, minced adipose tissue was cultured with recombinant SAA (2.34 mug ml -1), and the conditioned medium was collected from 24 to 48 h of incubation for adiponectin assay. 
###end p 48
###begin title 49
Effect of SAA on Lipolysis
###end title 49
###begin p 50
###xml 105 107 104 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 197 199 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b024">24</xref>
Minced adipose tissue samples were cultured with recombinant SAA at a final concentration of 2.34 mug ml -1. After 24 h, medium was collected and glycerol was measured using a fluorometric assay [ 24] to assess changes in lipolysis in response to SAA. Data are presented as micromoles of glycerol per gram of adipose tissue in 24 h. 
###end p 50
###begin title 51
Cytokine Analysis
###end title 51
###begin p 52
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 361 366 <span type="species:ncbi:9606">Human</span>
###xml 431 436 <span type="species:ncbi:10090">mouse</span>
###xml 740 745 <span type="species:ncbi:9606">Human</span>
Human A-SAA (BioSource, Camarillo, California, United States) and PAI-1 (American Diagnostica, Greenwich, Connecticut, United States) were measured with ELISA kits according to instructions of the manufacturers. The SAA ELISA kit detects only A-SAA (SAA1 and SAA2) and not SAA4. The intra- and interassay coefficients of variation were 5% and 8%, respectively. Human monocyte chemoattractant protein-1 (MCP-1), IL-6, and IL-8; and mouse TNF-alpha, MCP-1, and RANTES in tissue culture media were analyzed at the Cytokine Core Facility, University of Maryland School of Medicine with cytokine multiplex reagents (Upstate Biotechnology, Lake Placid, New York, United States) by Luminex 100 (Luminex Corporation, Austin, Texas, United States). Human serum IL-6 and TNF-alpha levels were measured by high sensitive Quantikine enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, Minnesota, United States), and adiponectin levels were measured by radioimmunoassay (Linco, St. Charles, Michigan, United States). All samples were assayed in duplicate.
###end p 52
###begin title 53
Statistical Analysis
###end title 53
###begin p 54
###xml 262 263 260 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 568 570 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b025">25</xref>
###xml 729 730 727 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 499 511 <span type="species:ncbi:9606">participants</span>
Results are expressed as mean +/- standard error of the mean (SEM) unless otherwise specified. Variables that were not normally distributed were natural logarithm-transformed for analysis and back-transformed for presentation. The Student's two sample or paired t test was applied when appropriate, as specified in the figure legends. Significance of correlations between two variables was determined by the Spearman rank correlation coefficient. In order to control for relatedness among the Amish participants, variance components analysis as implemented in SOLAR [ 25] was used to assess the correlation between BMI and A-SAA levels in the larger set of 134 Amish individuals. Differences were considered to be significant at p < 0.05. 
###end p 54
###begin title 55
Results
###end title 55
###begin title 56
###xml 39 44 <span type="species:ncbi:9606">Human</span>
Acute-Phase SAA Is Highly Expressed in Human Adipocytes
###end title 56
###begin p 57
###xml 381 389 381 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g001">Figure 1</xref>
###xml 501 509 501 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g001">Figure 1</xref>
###xml 729 737 729 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g001">Figure 1</xref>
###xml 845 853 845 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g001">Figure 1</xref>
###xml 95 100 <span type="species:ncbi:9606">human</span>
###xml 346 351 <span type="species:ncbi:9606">human</span>
###xml 478 483 <span type="species:ncbi:9606">human</span>
###xml 558 563 <span type="species:ncbi:9606">human</span>
###xml 763 767 <span type="species:ncbi:10090">mice</span>
###xml 899 905 <span type="species:ncbi:9606">humans</span>
Microarray analysis of mRNA preferentially expressed in fat cells compared to stromal cells of human subcutaneous and omental adipose tissue pointed our attention to A-SAA (unpublished data). Semiquantitative RT-PCR analysis with primers fully and specifically matching SAA1 and SAA2 cDNAs validated the high level of expression of A-SAA mRNA in human adipocytes but not in SVCs ( Figure 1A). Northern analysis showed that A-SAA mRNA was selectively and abundantly expressed in human adipose tissue ( Figure 1B, left). The higher expression of A-SAA mRNA in human adipose compared to liver tissue (at least 15-fold) was confirmed in an independent Northern analysis containing additional specimens of adipose and liver tissues ( Figure 1B, right). Conversely, in mice, A-SAA mRNA was predominately expressed in liver but not in adipose tissue ( Figure 1C). These studies show, unexpectedly, that in humans, A-SAA is predominately expressed in adipose tissue, more specifically in adipocytes, and that the adipose expression is species-specific. 
###end p 57
###begin title 58
Obesity Is Associated with Increased Circulating Levels of A-SAA due to Increased Adipose A-SAA Gene Expression and Secretion
###end title 58
###begin p 59
###xml 274 276 274 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 377 378 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 489 490 489 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 499 500 499 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 634 635 634 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 726 734 726 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g002">Figure 2</xref>
###xml 761 763 761 763 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 786 788 786 788 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 807 809 805 807 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 839 841 835 837 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 1001 1002 997 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 549 552 <span type="species:ncbi:9606">men</span>
###xml 557 562 <span type="species:ncbi:9606">women</span>
Selective and abundant A-SAA expression in adipocytes suggests that obesity may be associated with increased circulating A-SAA levels. To test this hypothesis, we measured plasma A-SAA levels in 19 age- and sex-matched nondiabetic sibling pairs who were discordant (>3 kg m -2) for BMI. A paired t-test showed significantly higher plasma A-SAA levels in the heavier siblings ( p = 0.044) and a positive Spearman correlation coefficient was observed between the BMI and A-SAA differences ( r = 0.54, p = 0.017). In an expanded set of 134 nondiabetic men and women over a range of BMIs, BMI was a significant predictor of A-SAA level ( p = 0.025, controlling for age, sex, and family structure). When individuals were grouped ( Figure 2) into lean (BMI < 25 kg m -2), overweight (25 kg m -2 </= BMI < 30 kg m -2), and obese (BMI >/= 30 kg m -2), the mean plasma A-SAA level of the obese group (ln-transformed for analysis, back-transformed for presentation) was 43% higher than that of the lean group ( p = 0.013, adjusted for age, sex and family structure). 
###end p 59
###begin p 60
###xml 493 494 493 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 503 504 503 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 514 515 514 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 522 530 522 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g003">Figure 3</xref>
###xml 618 619 618 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 628 629 628 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 640 641 640 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 648 656 648 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g003">Figure 3</xref>
###xml 841 842 841 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 851 852 851 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 862 863 862 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 953 954 953 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 963 964 963 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 973 974 973 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 981 989 981 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g003">Figure 3</xref>
###xml 336 341 <span type="species:ncbi:9606">women</span>
Increased serum A-SAA levels in obesity could be the result of normal expression and secretion of A-SAA from an increased fat mass, and/or increased expression and secretion of A-SAA from dysfunctional adipose or other tissues. To distinguish between these possibilities, adipose tissue samples were obtained from healthy premenopausal women over a range of BMIs, and A-SAA mRNA expression and secretion were measured. Adipose tissue A-SAA mRNA levels were significantly correlated with BMI ( r = 0.47, p = 0.028, n = 22; Figure 3A). Moreover, SAA release per gram of adipose tissue was strongly correlated with BMI ( r = 0.80, p = 0.0002, n = 16; Figure 3B). Furthermore, there was a strong correlation between adipose A-SAA gene expression and secretion in seven of these individuals who had both A-SAA mRNA and A-SAA secretion measured ( r = 0.89, p = 0.007, n = 7). A-SAA gene expression was also positively correlated with average adipocyte size ( r = 0.47, p = 0.04, n = 19; Figure 3C). These data suggest that increased A-SAA secretion from adipose tissue in obesity is the result of both increased fat mass and an increased rate of secretion per unit of adipose tissue. 
###end p 60
###begin title 61
Changes in A-SAA Levels Are Associated with Outcomes of Clinical Interventions: Effect of Weight Loss and Rosiglitazone Therapy
###end title 61
###begin p 62
###xml 405 407 403 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 553 554 545 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 564 565 556 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 579 580 571 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 695 696 687 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 705 706 697 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 715 716 707 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 743 744 735 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 753 754 745 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 765 773 757 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g004">Figure 4</xref>
###xml 816 817 808 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 826 827 818 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1065 1066 1057 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1076 1077 1068 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 437 442 <span type="species:ncbi:9606">women</span>
###xml 852 864 <span type="species:ncbi:9606">participants</span>
###xml 1285 1290 <span type="species:ncbi:9606">women</span>
If A-SAA is a marker of or causal link between obesity and its metabolic and cardiovascular complications, we would predict that circulating A-SAA levels would decrease in response to interventions that decrease obesity or its metabolic complications, e.g., insulin resistance. We measured serum A-SAA levels before and after weight loss with a hypocaloric diet program in 33 obese (BMI 32.3 +/- 4.0 kg m -2; mean +/- SD) postmenopausal women. A mean (+/- SEM) weight loss of 6.0 +/- 0.7 kg or 7.1% was associated with a 13.8% reduction in SAA levels ( p = 0.006, n = 33; paired t-test). Significantly, the relative changes in serum A-SAA concentration correlated with relative changes in BMI ( r = 0.39, p = 0.03, n = 33) and body fat mass ( r = 0.35, p = 0.04) ( Figure 4), but not with changes of fat free mass ( r = 0.23, p = 0.30). Eight of these participants also underwent hyperinsulinemic-euglycemic clamps before and after the weight loss intervention. In response to weight loss, increases in insulin sensitivity were correlated with decreases in A-SAA ( r = -0.74, p = 0.034). These findings suggest that A-SAA falls in response to weight loss and that a decrease in A-SAA partially predicts the increase in insulin sensitivity seen with weight loss in obese postmenopausal women. 
###end p 62
###begin p 63
###xml 291 293 289 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 619 620 615 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 632 640 628 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g005">Figure 5</xref>
###xml 816 824 812 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g005">Figure 5</xref>
###xml 1062 1070 1058 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g005">Figure 5</xref>
###xml 1174 1175 1170 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 745 757 <span type="species:ncbi:9606">participants</span>
###xml 1035 1046 <span type="species:ncbi:9606">participant</span>
We next reasoned that if A-SAA was an inflammatory adipokine involved in the metabolic consequences of obesity, other interventions that influence inflammation and insulin sensitivity might alter A-SAA concentrations. Eight overweight or obese nondiabetic individuals (BMI 30.8 +/- 3.1 kg m -2, mean +/- SD) were treated for 12 wk with rosiglitazone, a drug with insulin sensitizing and anti-inflammatory actions. There were no statistically significant changes in body weight or fat mass in these individuals during the 12-wk intervention. Nevertheless, serum A-SAA levels decreased by a mean of 37% after treatment ( p = 0.033) ( Figure 5A). Moreover, the secretion of A-SAA from adipose tissue explants obtained by aspiration from these same participants was significantly reduced after rosiglitazone treatment ( Figure 5B). The extent of serum A-SAA decrease tended to correlate with that of adipose A-SAA secretion, although the correlation was not statistically significant, presumably due to the small sample size. Notably, one participant (green line in Figure 5) responded to rosiglitazone with a marked reduction in A-SAA. Exclusion of this individual changed the p-values for serum and adipose SAA secretion from 0.033 and 0.034 to 0.001 and 0.055, respectively. Thus, rosiglitazone reduced adipose A-SAA secretion and lowered serum A-SAA levels with no significant change in BMI or fat mass. 
###end p 63
###begin p 64
###xml 699 700 699 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 712 720 712 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g006">Figure 6</xref>
###xml 352 364 <span type="species:ncbi:9606">participants</span>
The mechanism by which rosiglitazone decreases adipose A-SAA secretion could be direct, through action on adipose tissue, or indirect, through its effects on circulating hormones or other factors. Thus, we further investigated whether rosiglitazone acted directly on adipose tissue to decrease A-SAA secretion. Adipose tissue obtained from nondiabetic participants was cultured ex vivo. Incubation of the fat explants for 2 d with insulin or dexamethasone resulted in an SAA accumulation in the medium, and combination of the two hormones was additive in the stimulatory effect. Addition of rosiglitazone in the presence of insulin and dexamethasone reduced A-SAA secretion into the medium by 70% ( p = 0.002) ( Figure 6). These findings indicate that rosiglitazone acts directly on adipose tissue to suppress A-SAA production by adipocytes. 
###end p 64
###begin title 65
SAA Is a Proinflammatory Cytokine
###end title 65
###begin p 66
###xml 426 428 425 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 451 453 449 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 762 770 756 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g007">Figure 7</xref>
###xml 811 813 805 807 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 276 281 <span type="species:ncbi:9606">human</span>
###xml 345 350 <span type="species:ncbi:10090">mouse</span>
We hypothesized that A-SAA, produced by adipocytes, may be a causal link between obesity, chronic systemic inflammation, and metabolic and cardiovascular consequences through stimulation of inflammatory cytokines locally in adipose tissue as well as at distant sites. Primary human coronary vascular endothelial cells (HCVECs), adipose SVCs and mouse RAW264 monocytes were treated with vehicle (PBS), or with low (0.47 mug ml -1) or high (2.34 mug ml -1) concentrations of SAA for 8 h, and the conditioned medium was assayed for cytokine production. SAA dramatically stimulated, in a dose-dependent manner, the release of IL-6, IL-8, MCP-1, and PAI-1 in HCVECs; IL-6, IL-8, and MCP-1 in adipose SVCs; and IL-6, RANTES, TNF-alpha, and MCP-1 in RAW264 monocytes ( Figure 7). Treatment of these cells with 1 ng ml -1 lipopolysaccharide, a concentration that is at least ten times higher than the maximum possible contamination of endotoxin in the recombinant SAA, did not stimulate inflammatory cytokine secretion in HCVECs or adipose SVCs. Thus, SAA is a potent proinflammatory adipokine. 
###end p 66
###begin title 67
SAA Stimulates Lipolysis
###end title 67
###begin p 68
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b026">26</xref>
###xml 303 305 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b027">27</xref>
###xml 318 320 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b028">28</xref>
###xml 591 592 583 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 604 612 596 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g008">Figure 8</xref>
###xml 417 422 <span type="species:ncbi:9606">human</span>
One mechanism by which obesity may be linked to insulin resistance is through increased lipolysis, which results in increased circulating levels of free fatty acids (FFAs) and decreased glucose uptake by muscle and liver [ 26]. Because chronic treatment with inflammatory adipokines such as TNF-alpha [ 27] and IL-6 [ 28] increase basal lipolysis, we next examined whether SAA might have a similar effect. Culture of human adipose tissue treated with SAA for 24 h significantly increased lipolysis, as measured by glycerol accumulation in the incubation medium by 47% +/- 11% (mean +/- SEM, p = 0.001) ( Figure 8). 
###end p 68
###begin title 69
SAA Versus Adiponectin, IL-6, and TNF-alpha
###end title 69
###begin p 70
###xml 254 256 253 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 467 469 466 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 475 477 474 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 515 516 510 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 525 526 520 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 748 749 743 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 758 759 753 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 770 771 765 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 904 905 899 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 915 916 910 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 925 926 920 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 202 207 <span type="species:ncbi:9606">human</span>
###xml 594 599 <span type="species:ncbi:9606">human</span>
###xml 600 612 <span type="species:ncbi:9606">participants</span>
Another mechanism by which adipose secretion of SAA might link obesity with insulin resistance is through down-regulation of adiponectin expression and/or secretion. To test this hypothesis, we treated human adipose tissue explants with SAA (2.34 mug ml -1) and measured adiponectin secretion into the medium. We found that SAA tended to reduce adiponectin secretion, but the difference did not reach statistical significance (basal versus SAA treatment [ng g tissue -1 24 h -1], 2.80 +/- 1.6 versus 2.34 +/- 1.27, p = 0.07, n = 9]. We further examined whether the levels of A-SAA in plasma of human participants over a wide range of BMIs were correlated with those of adiponectin. Although adiponectin levels were negatively correlated with BMI ( r = -0.3, p < 0.0001, n = 157), and SAA levels were correlated with BMI (see above), there was no correlation between the levels of A-SAA and adiponectin ( r = 0.049, p = 0.45, n = 157). These findings do not support a role of adiponectin in SAA-mediated pathways of insulin resistance. 
###end p 70
###begin p 71
###xml 185 186 181 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 195 196 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 205 206 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 245 246 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 256 257 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 266 267 258 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 387 388 375 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 397 398 385 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 407 408 395 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 123 128 <span type="species:ncbi:9606">women</span>
We further examined the relationship of serum A-SAA levels with IL-6 and TNF-alpha in a population of postmenopausal obese women. Serum A-SAA is positively correlated with serum IL-6 ( r = 0.54, p = 0.03, n = 16), but not with serum TNF-alpha ( r = -0.30, p = 0.11, n = 30), which is consistent with the observation that there is no correlation between serum IL-6 and TNF-alpha levels ( r = 0.03, p = 0.93, n = 16). This finding suggests that common mechanisms may regulate A-SAA and IL-6. 
###end p 71
###begin title 72
Discussion
###end title 72
###begin p 73
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b029">29</xref>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b031">31</xref>
###xml 387 390 387 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SAA</italic>
###xml 438 446 438 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(SAA1&#8211;4)</italic>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b032">32</xref>
###xml 529 541 529 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(SAA1, SAA2,</italic>
###xml 546 552 546 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SAA4),</italic>
###xml 561 565 561 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SAA3</italic>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b033">33</xref>
###xml 806 808 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b034">34</xref>
###xml 972 974 972 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b035">35</xref>
###xml 497 503 <span type="species:ncbi:9606">humans</span>
Increasing evidence supports the hypothesis that the low-grade chronic systemic inflammation associated with obesity may be an important mediator of the metabolic syndrome and its constituents, including insulin resistance, type 2 diabetes, dyslipidemia, and hypertension [ 29- 31]. However, the molecular and cellular mechanisms that link obesity to inflammation are poorly understood. SAA is a multigene family consisting of four genes (SAA1-4) that are conserved in major vertebrates [ 32]. In humans, three of the four genes (SAA1, SAA2, and SAA4), but not SAA3 (a pseudogene), are expressed [ 33]. In response to acute inflammatory stimuli, SAA1 and SAA2 levels in plasma can increase as much as 1,000-fold within 5-6 h and therefore, SAA1 and SAA2 are collectively known as acute-phase SAA (A-SAA) [ 34]. As with other acute-phase reactants, e.g., C-reactive protein, and based on animal studies, the liver is thought to be the primary source of circulating A-SAA [ 35]. 
###end p 73
###begin p 74
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b013">13</xref>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b014">14</xref>
###xml 368 372 368 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SAA3</italic>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b036">36</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b033">33</xref>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b015">15</xref>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b016">16</xref>
###xml 38 44 <span type="species:ncbi:9606">humans</span>
###xml 233 239 <span type="species:ncbi:9606">humans</span>
###xml 264 268 <span type="species:ncbi:10090">mice</span>
###xml 361 367 <span type="species:ncbi:10090">murine</span>
###xml 432 438 <span type="species:ncbi:9606">humans</span>
In this study, we demonstrate that in humans, A-SAA (both SAA1 and SAA2) is predominantly expressed in adipose tissue, specifically adipocytes. Others have recently reported similar findings [ 13, 14]. Adipose expression of A-SAA in humans is in sharp contrast to mice, in which A-SAA is expressed predominantly in liver. There is a report of the expression of murine SAA3 in adipose tissue [ 36], but this gene is not expressed in humans [ 33]. Similar to the results of other investigators [ 15, 16], we found that circulating A-SAA levels are elevated in obese compare to lean individuals and, furthermore, that A-SAA expression is correlated with BMI and fat cell size. Collectively, these results strongly support adipose SAA as a major source of circulating SAA, particularly in obese individuals. 
###end p 74
###begin p 75
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b013">13</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b014">14</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b037">37</xref>
###xml 638 640 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b038">38</xref>
###xml 792 794 788 790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b017">17</xref>
###xml 796 798 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b018">18</xref>
###xml 800 802 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b039">39</xref>
###xml 1069 1071 1061 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b040">40</xref>
###xml 547 554 <span type="species:ncbi:9606">persons</span>
Is A-SAA a marker of excess and/or dysfunctional adipose tissue and inflammation or is it a causal link between obesity, inflammation, and metabolic and cardiovascular sequelae? We demonstrated that interventions that are known to decrease chronic inflammation and improve the metabolic and cardiovascular consequences of obesity, such as weight loss and rosiglitazone treatment, also decrease adipose A-SAA expression and secretion as well as circulating A-SAA levels. Similar findings with regard to serum A-SAA levels were recently reported in persons who underwent weight loss [ 13, 14, 37], and in those treated with rosiglitazone [ 38]. Furthermore, previous studies indicated that A-SAA is a potent stimulus for the expression and release of TNF-alpha, IL-6, and IL-8 in neutrophils [ 17, 18, 39]. We showed also that A-SAA directly stimulates the production of inflammatory cytokines in coronary artery endothelial cells and monocytes, as well as locally by adipose tissue SVCs. Others have shown that A-SAA is induced by TNF-alpha and IL-6 in hepatoma cells [ 40], suggesting positive feedback between A-SAA and other cytokines. Collectively, these findings implicate A-SAA as a local and systemic proinflammatory adipokine, and not just a marker of inflammation. 
###end p 75
###begin p 76
###xml 141 143 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b041">41</xref>
###xml 153 155 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b042">42</xref>
###xml 170 172 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b043">43</xref>
###xml 220 222 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b044">44</xref>
###xml 316 318 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b042">42</xref>
###xml 320 322 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b045">45</xref>
###xml 416 424 412 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g001">Figure 1</xref>
###xml 723 725 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b010">10</xref>
###xml 727 729 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b011">11</xref>
###xml 945 947 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b010">10</xref>
###xml 1168 1176 1164 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g009">Figure 9</xref>
The increased mass of dysfunctional adipose tissue in obesity is known to be a source of several inflammatory factors, including TNF-alpha [ 41], IL-6 [ 42], and MCP-1 [ 43], and also of the prothrombotic factor PAI-1 [ 44]. These proinflammatory cytokines are predominantly products of SVCs within adipose tissue [ 42, 45]. By contrast, A-SAA, like leptin and adiponectin, is a product of adipocytes and not SVCs ( Figure 1A). Our finding that SAA potently stimulates the secretion of proinflammatory cytokines in adipose SVCs suggests that adipocyte A-SAA acts as a paracrine factor to enhance cytokine production by SVCs. In addition, obesity is associated with increased infiltration of adipose tissue by macrophages [ 10, 11], which may also be target cells of SAA action. SAA may also be a chemoattractant for macrophages, raising a possible link for the association of fat cell size with macrophage infiltration in obese adipose tissue [ 10]. Thus, A-SAA may act locally to alter cytokine production and fat metabolism as well as systemically on liver, muscle, cells of the immune system, and the vasculature, to impact insulin resistance and atherosclerosis ( Figure 9). 
###end p 76
###begin p 77
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b046">46</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b047">47</xref>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b048">48</xref>
The signaling pathways of the A-SAA-mediated inflammation response are not well studied. In neutrophils, SAA induces IL-8 production through the formyl peptide receptor-like 1/lipoxin A4 receptor and activates nuclear factor kappa B [ 46]. The same signaling pathway recently has been shown to be an important mediator of inflammation-associated insulin resistance [ 47, 48]. Whether the induction of cytokine production by A-SAA in vascular endothelial cells and SVCs, as we have shown here, occurs through the same mechanism remains to be determined. 
###end p 77
###begin p 78
###xml 116 120 116 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SAA1</italic>
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SAA2</italic>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b038">38</xref>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b049">49</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b050">50</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b051">51</xref>
Our findings that rosiglitazone treatment significantly reduces A-SAA secretion and serum A-SAA levels suggest that SAA1 and SAA2 may be target genes of peroxisome proliferator-activated receptor-gamma. Both in vitro and in clinical studies, rosiglitazone exhibits anti-inflammatory properties [ 38, 49, 50], which are likely to be beneficial in slowing or reversing atherosclerosis [ 51]. Thus, the suppression of A-SAA may be a significant component of the anti-inflammatory and antiatherogenic action of peroxisome proliferator-activated receptor-gamma agonists, providing evidence that agents that inhibit A-SAA secretion or action may be efficacious for treatment of the metabolic syndrome and atherosclerosis. 
###end p 78
###begin p 79
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b026">26</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b052">52</xref>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b028">28</xref>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b027">27</xref>
###xml 388 396 388 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g003">Figure 3</xref>
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b053">53</xref>
###xml 919 921 915 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b027">27</xref>
Obesity is associated with increased basal lipolysis in adipose tissue [ 26] and elevated circulating FFAs that are thought to elicit systemic insulin resistance [ 52]. We also discovered that SAA, like IL6 [ 28] and TNF [ 27], has a long-term effect in stimulating basal lipolysis. The lipolytic activity of SAA can be an autocrine feedback mechanism by which increased SAA production ( Figure 3) from enlarged adipocytes limits further triacylglycerol accumulation. The resulting increased release of FFA into the circulation may contribute to insulin resistance. The mechanism of SAA-mediated lipolysis is under investigation. A recent study indicated that SAA binds CLA-1 (CD36 and LIMPII Analogous-1), resulting in activation of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinases [ 53]. Extracellular signal-regulated kinase activation is involved in TNF-alpha-induced lipolysis [ 27]. CLA-1 is highly expressed in adipose tissue (unpublished data). Thus, SAA may act through CLA-1 and the extracellular signal-regulated kinase signaling pathway to stimulate lipolysis directly. Alternatively, increased lipolysis by SAA might be indirect, through its stimulation of other lipolytic cytokines, e.g., IL-6 and TNF-alpha. 
###end p 79
###begin p 80
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b054">54</xref>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b055">55</xref>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b056">56</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b029">29</xref>
###xml 658 666 658 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0030287-g009">Figure 9</xref>
Recent studies suggest that in addition to its role in inflammation, A-SAA may play a direct physiological role in cholesterol metabolism. SAA is an apolipoprotein and a component of high-density lipoprotein (HDL) particles [ 54]. The interaction of SAA with HDL may impair the function of HDL as an antiatherogenic molecule [ 55] and facilitate its degradation [ 56]. Dyslipidemia, including low HDL-cholesterol (HDL-C), is a metabolic consequence of obesity and a component of the metabolic syndrome [ 29]. Thus, the increase of adipose-derived SAA in obesity that we observed may be a mechanistic link between obesity, low HDL-C, and increased CVD risk ( Figure 9). 
###end p 80
###begin p 81
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b005">5</xref>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b057">57</xref>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b058">58</xref>
###xml 511 512 511 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b005">5</xref>
###xml 718 719 718 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0030287-b007">7</xref>
###xml 271 277 <span type="species:ncbi:9606">humans</span>
###xml 590 602 <span type="species:ncbi:9606">participants</span>
###xml 610 615 <span type="species:ncbi:9606">Women</span>
###xml 650 655 <span type="species:ncbi:9606">Women</span>
CRP is an acute-phase reactant produced in the liver and a marker of chronic low-grade inflammation. Modest elevation in CRP is associated with increased CVD risk in epidemiological studies [ 5, 57, 58]. In contrast to A-SAA, CRP is barely expressed in adipose tissue in humans (unpublished data). If A-SAA is a direct mediator of obesity-associated inflammation and its metabolic and cardiovascular consequences, might serum A-SAA be a better indicator of obesity-associated CVD risk than CRP? Ridker et al. [ 5] showed that both CRP and A-SAA levels confer similar risk for CVD events in participants of the Women's Health Study. Similarly, in the Women's Ischemia Syndrome Evaluation (WISE) Study, Johnson et al. [ 7] recently reported that SAA is independently associated with angiographic coronary artery disease and highly predictive of 3-y cardiovascular events. These studies did not specifically address the relationship between BMI and A-SAA (or CRP) in predicting CVD events. Our studies suggest that A-SAA may be a valuable diagnosticand prognostic marker of obesity-associated CVD risk and possibly of the effects of interventions such as weight loss and rosiglitazone therapy. Additional studies are needed to better define the biology and clinical utility of A-SAA and to further establish A-SAA as a causal link between obesity and inflammation and their cardiovascular consequences. 
###end p 81
###begin title 82
Supporting Information
###end title 82
###begin title 83
Chinese Translation of the Abstract by RZY and DWG
###end title 83
###begin p 84
(21 KB DOC)
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin p 86
We thank Nikki Glynn for her technical assistance.
###end p 86
###begin p 87
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. RZY, MJL, ASR, BJN, APG, ARS, SKF, and DWG designed the study. RZY, MJL, HH, ASR, BJN, SS, RBH, KH, NHG, and DWG performed the experiments. RZY, MJL, TIP, ASR, BJN, and DWG analyzed the data. RZY, MJL, ASR, BJN, RBH, APG, ARS, SKF, and DWG contributed to writing the paper. 
###end p 87
###begin title 88
References
###end title 88
###begin article-title 89
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
###end article-title 89
###begin article-title 90
###xml 30 35 <span type="species:ncbi:9606">human</span>
Role of insulin resistance in human disease (syndrome X): An expanded definition
###end article-title 90
###begin article-title 91
Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association
###end article-title 91
###begin article-title 92
Cardiovascular morbidity and mortality associated with the metabolic syndrome
###end article-title 92
###begin article-title 93
###xml 100 105 <span type="species:ncbi:9606">women</span>
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
###end article-title 93
###begin article-title 94
C-reactive protein levels and outcomes after statin therapy
###end article-title 94
###begin article-title 95
###xml 88 93 <span type="species:ncbi:9606">women</span>
###xml 151 156 <span type="species:ncbi:9606">Women</span>
Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE)
###end article-title 95
###begin article-title 96
A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease
###end article-title 96
###begin article-title 97
Inflamed about obesity
###end article-title 97
###begin article-title 98
Obesity is associated with macrophage accumulation in adipose tissue
###end article-title 98
###begin article-title 99
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance
###end article-title 99
###begin article-title 100
Obesity wars: Molecular progress confronts an expanding epidemic
###end article-title 100
###begin article-title 101
###xml 31 36 <span type="species:ncbi:9606">human</span>
Serum amyloid A: Production by human white adipocyte and regulation by obesity and nutrition
###end article-title 101
###begin article-title 102
###xml 57 62 <span type="species:ncbi:9606">human</span>
A microarray search for genes predominantly expressed in human omental adipocytes: Adipose tissue as a major production site of serum amyloid A
###end article-title 102
###begin article-title 103
Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals
###end article-title 103
###begin article-title 104
The association of c-reactive protein, serum amyloid A and fibrinogen with prevalent coronary heart disease-Baseline findings of the PAIS project
###end article-title 104
###begin article-title 105
###xml 143 148 <span type="species:ncbi:9606">human</span>
A novel function of serum amyloid A: A potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil
###end article-title 105
###begin article-title 106
###xml 98 103 <span type="species:ncbi:9606">human</span>
Serum amyloid A-induced mRNA expression and release of tumor necrosis factor-alpha (TNF-alpha) in human neutrophils
###end article-title 106
###begin article-title 107
###xml 42 47 <span type="species:ncbi:9606">women</span>
Insulin resistance in adipocytes of obese women: Effects of body fat distribution and race
###end article-title 107
###begin article-title 108
Diabetes in the Old Order Amish: Characterization and heritability analysis of the Amish Family Diabetes Study
###end article-title 108
###begin article-title 109
###xml 121 126 <span type="species:ncbi:9606">women</span>
Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women
###end article-title 109
###begin article-title 110
A reliable photomicrographic method to determining fat cell size and number: Application to dietary obesity
###end article-title 110
###begin article-title 111
###xml 42 47 <span type="species:ncbi:9606">human</span>
Cachectin/tumor necrosis factor decreases human adipose tissue lipoprotein lipase mRNA levels, synthesis, and activity
###end article-title 111
###begin article-title 112
An enzymatic fluorometric micromethod for the determination of glycerol
###end article-title 112
###begin article-title 113
Multipoint quantitative-trait linkage analysis in general pedigrees
###end article-title 113
###begin article-title 114
###xml 68 71 <span type="species:ncbi:9606">man</span>
Control of lipolysis and its relevance to development of obesity in man
###end article-title 114
###begin article-title 115
TNF-alpha induction of lipolysis is mediated through activation of the extracellular signal related kinase pathway in 3T3-L1 adipocytes
###end article-title 115
###begin article-title 116
###xml 24 29 <span type="species:ncbi:9606">human</span>
Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro
###end article-title 116
###begin article-title 117
Metabolic syndrome
###end article-title 117
###begin article-title 118
Adipose tissue, insulin action and vascular disease: Inflammatory signals
###end article-title 118
###begin article-title 119
Diabesity: An inflammatory metabolic condition
###end article-title 119
###begin article-title 120
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human serum amyloid A protein (SAA) superfamily gene cluster: Mapping to chromosome 11p15.1 by physical and genetic linkage analysis
###end article-title 120
###begin article-title 121
###xml 27 55 27 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">serum amyloid A three (SAA3)</italic>
###xml 21 26 <span type="species:ncbi:9606">human</span>
Nonexpression of the human serum amyloid A three (SAA3) gene 
###end article-title 121
###begin article-title 122
Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein
###end article-title 122
###begin article-title 123
Acute-phase proteins and other systemic responses to inflammation
###end article-title 123
###begin article-title 124
Hyperglycemia-induced production of acute phase reactants in adipose tissue
###end article-title 124
###begin article-title 125
Diet-induced weight loss is associated with decreases in plasma serum amyloid A and C-reactive protein independent of dietary macronutrient composition in obese subjects
###end article-title 125
###begin article-title 126
Evidence for a potent antiinflammatory effect of rosiglitazone
###end article-title 126
###begin article-title 127
mRNA expression and release of interleukin-8 induced by serum amyloid A in neutrophils and monocytes
###end article-title 127
###begin article-title 128
###xml 18 23 <span type="species:ncbi:9606">human</span>
Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines
###end article-title 128
###begin article-title 129
Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance
###end article-title 129
###begin article-title 130
Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid
###end article-title 130
###begin article-title 131
Monocyte chemoattractant protein 1 in obesity and insulin resistance
###end article-title 131
###begin article-title 132
Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity
###end article-title 132
###begin article-title 133
###xml 40 45 <span type="species:ncbi:9606">human</span>
TNFalpha release by the nonfat cells of human adipose tissue
###end article-title 133
###begin article-title 134
Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R
###end article-title 134
###begin article-title 135
Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB
###end article-title 135
###begin article-title 136
IKK-beta links inflammation to obesity-induced insulin resistance
###end article-title 136
###begin article-title 137
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
###end article-title 137
###begin article-title 138
PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
###end article-title 138
###begin article-title 139
Peroxisome proliferator-activated receptor gamma: Implications for cardiovascular disease
###end article-title 139
###begin article-title 140
Role of fatty acids in the pathogenesis of insulin resistance and NIDDM
###end article-title 140
###begin article-title 141
Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases
###end article-title 141
###begin article-title 142
SAA, an apoprotein of HDL: Its structure and function
###end article-title 142
###begin article-title 143
Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures
###end article-title 143
###begin article-title 144
High-density lipoproteins in sepsis and septic shock: Metabolism, actions, and therapeutic applications
###end article-title 144
###begin article-title 145
Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS)
###end article-title 145
###begin article-title 146
###xml 136 139 <span type="species:ncbi:9606">men</span>
C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992
###end article-title 146
###begin title 147
Abbreviations
###end title 147
###begin p 148
acute-phase serum amyloid protein A
###end p 148
###begin p 149
body mass index
###end p 149
###begin p 150
C-reactive protein
###end p 150
###begin p 151
cardiovascular disease
###end p 151
###begin p 152
free fatty acid
###end p 152
###begin p 153
high-density lipoprotein
###end p 153
###begin p 154
interleukin
###end p 154
###begin p 155
monocyte chemoattractant protein-1
###end p 155
###begin p 156
plasminogen activator inhibitor-1
###end p 156
###begin p 157
standard deviation
###end p 157
###begin p 158
standard error of the mean
###end p 158
###begin p 159
stromal-vascular cell
###end p 159
###begin p 160
tumor necrosis factor-alpha
###end p 160
###begin title 161
Figures and Tables
###end title 161
###begin title 162
Tissue-Restricted Expression of A-SAA mRNA
###end title 162
###begin p 163
###xml 122 127 <span type="species:ncbi:9606">human</span>
(A) Representative semiquantitative RT-PCR analysis of A-SAA and beta-actin mRNA in SVCs and adipocytes fractionated from human omental (O) and subcutaneous (S) adipose tissues.
###end p 163
###begin p 164
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
###xml 255 260 <span type="species:ncbi:9606">human</span>
###xml 268 274 <span type="species:ncbi:10090">murine</span>
###xml 485 497 <span type="species:ncbi:9606">participants</span>
(B and C) Northern analyses of multiple tissue blots from the human and mouse, respectively. For all Northern analyses, 15 mug of total RNA from the indicated tissues were electrophoresed, blotted onto a nylon membrane, and hybridized with a radiolabeled human (B) or murine (C) SAA2 cDNA probe, which detects both SAA1 and SAA2 (upper gels). Equality of RNA loadings was estimated by ethidium bromide staining (lower gels). Comparison of A-SAA expression was made in five independent participants (B, right). Epi, epididymal; SubQ, subcutaneous
###end p 164
###begin title 165
Circulating A-SAA Levels are Positively Correlated with BMI
###end title 165
###begin p 166
###xml 108 110 108 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 112 113 112 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 148 150 148 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 152 153 152 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 187 189 185 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 191 192 189 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 355 356 351 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 47 52 <span type="species:ncbi:9606">human</span>
###xml 53 65 <span type="species:ncbi:9606">participants</span>
A-SAA levels were measured in plasma of normal human participants who were divided into lean (BMI < 25 kg m -2, n = 54), overweight (BMI 25-30 kg m -2, n = 49) and obese (BMI >/= 30 kg m -2, n = 31) groups. Data are expressed as mean +/- SEM (ln-transformed for analysis, back-transformed for presentation), adjusted for age, sex, and family structure. * p = 0.013 versus lean group. 
###end p 166
###begin title 167
Adipose A-SAA Gene Expression and Secretion Are Increased with BMI
###end title 167
###begin p 168
Adipose A-SAA mRNA levels, measured by quantitative real-time RT-PCR (top) and A-SAA release by adipose tissue (middle), were significantly correlated with BMI. Furthermore, adipose A-SAA mRNA levels were increased with the adipocyte size (bottom). Dotted lines indicate 95% confidence intervals.
###end p 168
###begin title 169
Reductions of Serum A-SAA and Fat Mass are Correlated
###end title 169
###begin p 170
Correlation between changes in serum A-SAA levels and changes in body fat mass before and after weight loss. Dotted lines indicate 95% confidence intervals.
###end p 170
###begin title 171
###xml 73 79 <span type="species:ncbi:9606">Humans</span>
Rosiglitazone Reduces Serum A-SAA Levels and Adipose A-SAA Production in Humans
###end title 171
###begin p 172
###xml 14 15 14 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 68 69 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 392 393 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 406 407 406 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 438 439 438 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 113 125 <span type="species:ncbi:9606">participants</span>
###xml 320 326 <span type="species:ncbi:9606">person</span>
Serum A-SAA ( n = 8) (top) and adipose secretion of A-SAA ex vivo ( n = 7) (bottom) were measured in nondiabetic participants before and after 3 mo of rosiglitazone treatment. The data are plotted with lines connecting the A-SAA levels of each individual. Serum A-SAA and adipose secretion of A-SAA (one symbol for same person of both studies) were significantly decreased by rosiglitazone ( p = 0.033 and p = 0.034, respectively; paired t-test after log-transformation). 
###end p 172
###begin title 173
Rosiglitazone Directly Suppresses A-SAA Production in Adipose Tissue
###end title 173
###begin p 174
###xml 333 334 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 366 367 363 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 379 380 376 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 401 402 398 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human adipose tissue explants were incubated in cell culture medium 199 (basal) or medium with insulin (Ins, 7 nM) and dexamethasone (Dex, 25 nM) in the presence or absence of rosiglitazone (Rosi, 1 muM) for 48 h. A-SAA production between 24 and 48 h was measured and corrected for tissue weight. Data are expressed as mean +/- SEM, n = 3 independent experiments. * p = 0.03, ** p = 0.002, two sample t-test after log-transformation. 
###end p 174
###begin title 175
SAA Is a Potent Proinflammatory Mediator
###end title 175
###begin p 176
###xml 186 188 185 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 225 227 223 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 406 407 402 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 467 468 463 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 480 481 476 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 501 502 497 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 98 103 <span type="species:ncbi:10090">mouse</span>
###xml 270 275 <span type="species:ncbi:9606">human</span>
Human coronary artery endothelial cells (HCAECs, A), adipose stromal vascular cells (SVCs, B) and mouse RAW264 monocytes (C) were treated with vehicle (PBS, white bar), low (0.47 mug ml -1, hatched bar), or high (2.34 mug ml -1, black bar) concentrations of recombinant human SAA for 8 h in serum-free medium. Cell-free supernatants were then assayed for cytokines. Data are expressed as mean +/- SEM from n = 3-5 independent experiments. Statistical significance (* p < 0.05; ** p < 0.01; two sample t-test) was observed between the SAA-treated groups and vehicle. 
###end p 176
###begin title 177
SAA Stimulates Lipolysis
###end title 177
###begin p 178
###xml 114 116 113 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 356 357 351 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 367 368 362 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Adipose tissues (eight subcutaneous and one omental) were cultured in the presence or absence of SAA (2.34 mug ml -1) for 24 h. SAA treatment increased lipolysis by 47% +/- 11% as assessed by measurement of glycerol accumulation in the culture medium. Data are expressed as mean +/- SEM (log-transformed for analysis, back-transformed for presentation). * p = 0.001, n = 9. 
###end p 178
###begin title 179
###xml 84 89 <span type="species:ncbi:9606">Human</span>
Schematic Diagram of Proposed Pathophysiological Role of Adipocyte-Derived A-SAA in Human Obesity
###end title 179
###begin p 180
A-SAA secreted from adipocytes acts locally on adipose SVCs to stimulate cytokine release and in adipocytes to stimulate lipolysis, increasing FFA release and decreasing insulin sensitivity in adipocytes, and possibly contributing to systemic dyslipidemia. In addition, A-SAA secretion by adipocytes into the circulation stimulates cytokine production at more distant sites, including in endothelial cells and monocytes, resulting in endothelial dysfunction, monocyte infiltration, accelerated atherosclerosis, and possibly insulin resistance in muscle and liver. A-SAA-stimulated lipolysis increases circulating FFA concentrations, further contributing to insulin resistance in muscle and liver. Finally, A-SAA incorporation into HDL accelerates its degradation and impairs its function, resulting in decreased HDL and accelerated atherosclerosis.
###end p 180
###begin p 181
Citation: Yang RZ, Lee MJ, Hu H, Pollin TI, Ryan AS, et al. (2006) Acute-phase serum amyloid A: An inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 3(6): e287. DOI: 10.1371/journal.pmed.0030287
###end p 181
###begin p 182
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: This work was supported by NIH grants DK57835 and DK62093 and an ADA Career Development Award (to DWG), R01 DK54261 and R01 DK56637 (to ARS), R01 DK52398 (to SKF), R01 AG18408 (to APG), K01 AG00747 and R01 AG19310 (to ASR), R29 A614066 (to BJN), T32 AG000219 (salary support for RBH), University of Maryland General Clinical Research Center Grant M01 RR16500, General Clinical Research Centers Program, National Center for Research Resources (NCRR), NIH, the Department of Veterans Affairs Medical Research Service, and the Baltimore Veterans Administration Medical Center Geriatric Research Education and Clinical Center (GRECC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 
###end p 182

